Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 33


The influence of biomechanical properties and cannabinoids on tumor invasion.

Hohmann T, Grabiec U, Ghadban C, Feese K, Dehghani F.

Cell Adh Migr. 2017 Jan 2;11(1):54-67. doi: 10.1080/19336918.2016.1183867. Epub 2016 May 5.


Fatty acid amide hydrolase inhibitors confer anti-invasive and antimetastatic effects on lung cancer cells.

Winkler K, Ramer R, Dithmer S, Ivanov I, Merkord J, Hinz B.

Oncotarget. 2016 Mar 22;7(12):15047-64. doi: 10.18632/oncotarget.7592.


Addition of DHA Synergistically Enhances the Efficacy of Regorafenib for Kidney Cancer Therapy.

Kim J, Ulu A, Wan D, Yang J, Hammock BD, Weiss RH.

Mol Cancer Ther. 2016 May;15(5):890-8. doi: 10.1158/1535-7163.MCT-15-0847. Epub 2016 Feb 26.


Potentiation of the antitumor activity of adriamycin against osteosarcoma by cannabinoid WIN-55,212-2.

Niu F, Zhao S, Xu CY, Sha H, Bi GB, Chen L, Ye L, Gong P, Nie TH.

Oncol Lett. 2015 Oct;10(4):2415-2421. Epub 2015 Jul 23.


Proapoptotic effect of endocannabinoids in prostate cancer cells.

Orellana-Serradell O, Poblete CE, Sanchez C, Castellón EA, Gallegos I, Huidobro C, Llanos MN, Contreras HR.

Oncol Rep. 2015 Apr;33(4):1599-608. doi: 10.3892/or.2015.3746. Epub 2015 Jan 21.


Cannabinoids as therapeutic agents in cancer: current status and future implications.

Chakravarti B, Ravi J, Ganju RK.

Oncotarget. 2014 Aug 15;5(15):5852-72. Review.


The influence of monoacylglycerol lipase inhibition upon the expression of epidermal growth factor receptor in human PC-3 prostate cancer cells.

Cipriano M, Gouveia-Figueira S, Persson E, Nording M, Fowler CJ.

BMC Res Notes. 2014 Jul 10;7:441. doi: 10.1186/1756-0500-7-441.


A novel activity of microsomal epoxide hydrolase: metabolism of the endocannabinoid 2-arachidonoylglycerol.

Nithipatikom K, Endsley MP, Pfeiffer AW, Falck JR, Campbell WB.

J Lipid Res. 2014 Oct;55(10):2093-102. doi: 10.1194/jlr.M051284. Epub 2014 Jun 23.


Potential upstream regulators of cannabinoid receptor 1 signaling in prostate cancer: a Bayesian network analysis of data from a tissue microarray.

Häggström J, Cipriano M, Forshell LP, Persson E, Hammarsten P, Stella N, Fowler CJ.

Prostate. 2014 Aug;74(11):1107-17. doi: 10.1002/pros.22827. Epub 2014 Jun 9.


Roles of Eicosanoids in Prostate Cancer.

Nithipatikom K, Campbell WB.

Future Lipidol. 2008 Aug 1;3(4):453-467.


The endocannabinoid system and sex steroid hormone-dependent cancers.

Ayakannu T, Taylor AH, Marczylo TH, Willets JM, Konje JC.

Int J Endocrinol. 2013;2013:259676. doi: 10.1155/2013/259676. Epub 2013 Nov 27. Review.


Critical appraisal of the potential use of cannabinoids in cancer management.

Cridge BJ, Rosengren RJ.

Cancer Manag Res. 2013 Aug 30;5:301-13. doi: 10.2147/CMAR.S36105. eCollection 2013. Review.


18F-MK-9470 PET imaging of the type 1 cannabinoid receptor in prostate carcinoma: a pilot study.

Emonds KM, Koole M, Casteels C, Van den Bergh L, Bormans GM, Claus F, De Wever L, Lerut E, Van Poppel H, Joniau S, Dumez H, Haustermans K, Mortelmans L, Goffin K, Van Laere K, Deroose CM, Mottaghy FM.

EJNMMI Res. 2013 Aug 2;3(1):59. doi: 10.1186/2191-219X-3-59.


Association between cannabinoid CB₁ receptor expression and Akt signalling in prostate cancer.

Cipriano M, Häggström J, Hammarsten P, Fowler CJ.

PLoS One. 2013 Jun 5;8(6):e65798. doi: 10.1371/journal.pone.0065798. Print 2013.


Therapeutic potential of monoacylglycerol lipase inhibitors.

Mulvihill MM, Nomura DK.

Life Sci. 2013 Mar 19;92(8-9):492-7. doi: 10.1016/j.lfs.2012.10.025. Epub 2012 Nov 8. Review.


The association of N-palmitoylethanolamine with the FAAH inhibitor URB597 impairs melanoma growth through a supra-additive action.

Hamtiaux L, Masquelier J, Muccioli GG, Bouzin C, Feron O, Gallez B, Lambert DM.

BMC Cancer. 2012 Mar 19;12:92. doi: 10.1186/1471-2407-12-92.


Monoacylglycerol lipase - a target for drug development?

Fowler CJ.

Br J Pharmacol. 2012 Jul;166(5):1568-85. doi: 10.1111/j.1476-5381.2012.01950.x. Review.


Cannabinoid receptor type 1 (CB1) activation inhibits small GTPase RhoA activity and regulates motility of prostate carcinoma cells.

Nithipatikom K, Gomez-Granados AD, Tang AT, Pfeiffer AW, Williams CL, Campbell WB.

Endocrinology. 2012 Jan;153(1):29-41. doi: 10.1210/en.2011-1144. Epub 2011 Nov 15. Erratum in: Endocrinology. 2012 May;153(5):2531.


Increasing antiproliferative properties of endocannabinoids in N1E-115 neuroblastoma cells through inhibition of their metabolism.

Hamtiaux L, Hansoulle L, Dauguet N, Muccioli GG, Gallez B, Lambert DM.

PLoS One. 2011;6(10):e26823. doi: 10.1371/journal.pone.0026823. Epub 2011 Oct 27.


Cannabinoids, endocannabinoids, and cancer.

Hermanson DJ, Marnett LJ.

Cancer Metastasis Rev. 2011 Dec;30(3-4):599-612. doi: 10.1007/s10555-011-9318-8. Review.

Supplemental Content

Support Center